Synairgen

Synairgen is a clinical-stage biopharmaceutical company developing an inhaled formulation of interferon beta as a broad-spectrum antiviral therapy for severe respiratory viral infections.

The approach stimulates the innate immune response directly in the lungs, targeting patients with severe viral pneumonia including those requiring mechanical ventilation.

A Phase 2 randomised controlled trial is currently enrolling patients across intensive care units in the UK, US, and Europe.